Company news
Pharmather Holdings Ltd (CSE:PHRM) news
Pharmather Holdings Ltd news releases on 6ix. Latest, Oct 5, 2026: PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate…
Press releases & updates
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
October 5, 2026
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
October 1, 2026
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
August 18, 2026
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
August 11, 2026
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
July 29, 2026
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
July 27, 2026
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
July 15, 2026
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
May 27, 2026
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
May 13, 2026
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
April 21, 2026
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
April 20, 2026
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
April 16, 2026
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
April 13, 2026
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
March 26, 2026
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
March 3, 2026
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
February 2, 2026
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
January 14, 2026
PharmaTher CEO Publishes Letter to Shareholders
January 2, 2026
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
December 2, 2025
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
November 17, 2025
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
October 17, 2025
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
October 16, 2025
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
October 15, 2025
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
October 8, 2025
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
October 2, 2025
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
October 1, 2025
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
August 27, 2025
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
August 26, 2025
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
August 14, 2025
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
August 14, 2025
PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
August 11, 2025
PharmaTher Announces FDA Approval of Ketamine (KETARx™)
August 11, 2025
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
July 2, 2025
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
June 24, 2025
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
June 18, 2025
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
May 16, 2025
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
May 14, 2025
PharmaTher Receives US FDA Approval Goal Date for Ketamine
March 11, 2025
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
March 3, 2025